| Literature DB >> 19725949 |
Emeka I Igwe1, Silke Essler, Natalie Al-Furoukh, Nathalie Dehne, Bernhard Brüne.
Abstract
BACKGROUND: Microarray analysis still is a powerful tool to identify new components of the transcriptosome. It helps to increase the knowledge of targets triggered by stress conditions such as hypoxia and nitric oxide. However, analysis of transcriptional regulatory events remain elusive due to the contribution of altered mRNA stability to gene expression patterns as well as changes in the half-life of mRNAs, which influence mRNA expression levels and their turn over rates. To circumvent these problems, we have focused on the analysis of newly transcribed (nascent) mRNAs by nuclear run on (NRO), followed by microarray analysis.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19725949 PMCID: PMC2743718 DOI: 10.1186/1471-2164-10-408
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Venn diagram of grouped genes. Analysis of gene expression in RAW cells subjected to hypoxia (1% O2) and/or 0.5 mM DETA-NO for 6 h. After removing double and unknown transcripts data represent total number of genes regulated by each treatment (in parentheses) as well as overlapping genes shared by treatments. A complete list of genes for each treatment is provided in the supplementary tables 1-3. Detailed information of genes from the intersections is given in table 1-5.
14 Genes common to all treatments; hypoxia, NO and hypoxia plus NO for 6 h.
| Bnip3 | BCL2/adenovirus E1B 19 kDa-interacting protein 1, NIP3 | 2.53 | 33.40 | 20.06 | |
| Ddit4 | DNA-damage-inducible transcript 4 | 5.19 | 19.68 | 35.21 | |
| Vegfa | vascular endothelial growth factor A | 2.06 | 9.08 | 6.55 | |
| Trib3 | tribbles homolog 3 (Drosophila) | 5.85 | 8.05 | 27.11 | |
| Atf3 | activating transcription factor 3 | 2.37 | 7.27 | 7.26 | |
| Cdkn1a | cyclin-dependent kinase inhibitor 1A (P21) | 2.07 | 2.89 | 4.25 | |
| Scd1 | stearoyl-Coenzyme A desaturase 1 | 4.18 | 2.54 | 3.55 | |
| D4Ertd765e | DNA segment, Chr 4, ERATO Doi 765, expressed | 2.91 | 2.52 | 2.30 | |
| Sesn2 | sestrin 2 | 3.47 | 2.32 | 5.23 | |
| Son | Son cell proliferation protein | -2.06 | -2.16 | -2.23 | |
| Nnt | nicotinamide nucleotide transhydrogenase | AK087064.1 | -2.04 | -2.39 | -2.41 |
| Lst1 | leukocyte specific transcript 1 | -2.26 | -2.62 | -2.55 | |
| Hps6 | Hermansky-Pudlak syndrome 6 | -4.86 | -3.74 | -4.21 | |
| Fxyd5 | FXYD domain-containing ion transport regulator 5 | BC031112.1 | -18.27 | -4.20 | -9.71 |
This list was obtained by comparing profiles of genes detected by the three treatments, excluding duplicate transcripts, unknown transcripts and transcripts not detected in one or two of the treatments. NO = nitric oxide (0.5 mM DETA-NO); Hyp = hypoxic treatment (1% O2).
18 Genes common to treatments with hypoxia or nitric oxide.
| Bnip3 | BCL2/adenovirus E1B 19 kDa-interacting protein 1, NIP3 | 2.53 | 33.40 | |
| Ddit4 | DNA-damage-inducible transcript 4 | 5.19 | 19.68 | |
| Vegfa | vascular endothelial growth factor A | 2.06 | 9.08 | |
| Trib3 | tribbles homolog 3 (Drosophila) | 5.85 | 8.05 | |
| Atf3 | activating transcription factor 3 | 2.37 | 7.27 | |
| Cdkn1a | cyclin-dependent kinase inhibitor 1A (P21) | 2.07 | 2.89 | |
| Scd1 | stearoyl-Coenzyme A desaturase 1 | 4.18 | 2.54 | |
| D4Ertd765e | DNA segment, Chr 4, ERATO Doi 765, expressed | 2.91 | 2.52 | |
| Frat2 | frequently rearranged in advanced T-cell lymphomas 2 | 2.15 | 2.49 | |
| Sesn2 | sestrin 2 | 3.47 | 2.32 | |
| Cd52 | CD52 antigen | -2.02 | -2.15 | |
| Son | Son cell proliferation protein | -2.06 | -2.16 | |
| Mafb | v-maf musculoaponeurotic fibrosarcoma oncogene family, protein B (avian) | -2.49 | -2.32 | |
| Nnt | nicotinamide nucleotide transhydrogenase | AK087064.1 | -2.04 | -2.39 |
| Ccl3 | chemokine (C-C motif) ligand 3 | X12531.1 | 2.22 | -2.42 |
| Lst1 | leukocyte specific transcript 1 | -2.26 | -2.62 | |
| Hps6 | Hermansky-Pudlak syndrome 6 | -4.86 | -3.74 | |
| Fxyd5 | FXYD domain-containing ion transport regulator 5 | BC031112.1 | -18.27 | -4.20 |
Gene transcripts regulated by hypoxia (1% O2) or NO (0.5 mM DETA-NO) were analyzed to identify overlapping genes in these set of data. Hyp = hypoxia treatment; NO = nitric oxide treatment.
Impact of hypoxia on genes regulated by NO.
| Ddit4 | DNA-damage-inducible transcript 4 | 5.19 | 35.21 | |
| Trib3 | tribbles homolog 3 (Drosophila) | 5.85 | 27.11 | |
| Bnip3 | BCL2/adenovirus E1B 19 kDa-interacting protein 1, NIP3 | 2.53 | 20.06 | |
| Phlda3 | pleckstrin homology-like domain, family A, member 3 | 3.88 | 9.41 | |
| Nqo1 | NAD(P)H dehydrogenase, quinone 1 | U12961.1 | 2.99 | 8.32 |
| Atf3 | activating transcription factor 3 | 2.37 | 7.26 | |
| Vegfa | vascular endothelial growth factor A | 2.06 | 6.55 | |
| Sesn2 | sestrin 2 | 3.47 | 5.23 | |
| Adh7 | alcohol dehydrogenase 7 (class IV), mu or sigma polypeptide | 2.71 | 5.06 | |
| Gpt2 | glutamic pyruvate transaminase (alanine aminotransferase) 2 | 2.49 | 5.02 | |
| Slc7a11 | solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 | 2.68 | 4.74 | |
| Cdkn1a | cyclin-dependent kinase inhibitor 1A (P21) | 2.07 | 4.25 | |
| Scd1 | stearoyl-Coenzyme A desaturase 1 | 4.18 | 3.55 | |
| Sfrs1 | splicing factor, arginine/serine-rich 1 (ASF/SF2) | 2.82 | 3.42 | |
| Slc19a2 | solute carrier family 19 (thiamine transporter), member 2 | 2.32 | 3.08 | |
| Atp6ap2 | ATPase, H+ transporting, lysosomal accessory protein 2 | 2.31 | 2.62 | |
| Txndc1 | thioredoxin domain containing 1 | 2.03 | 2.58 | |
| Adam10 | a disintegrin and metalloprotease domain 10 | 2.07 | 2.55 | |
| Lss | lanosterol synthase | AK012813.1 | 2.12 | 2.48 |
| Pmaip1 | phorbol-12-myristate-13-acetate-induced protein 1 | 2.27 | 2.46 | |
| Eif4g2 | eukaryotic translation initiation factor 4, gamma 2 | 2.16 | 2.45 | |
| Sgpp1 | sphingosine-1-phosphate phosphatase 1 | 3.00 | 2.42 | |
| Rbl2 | retinoblastoma-like 2 | 2.01 | 2.33 | |
| D4Ertd765e | DNA segment, Chr 4, ERATO Doi 765, expressed | 2.91 | 2.30 | |
| Vcl | vinculin | 2.02 | 2.22 | |
| Pabpc1 | poly A binding protein, cytoplasmic 1 | 2.11 | 2.19 | |
| Golph3 | golgi phosphoprotein 3 | 2.18 | 2.15 | |
| Rrm1 | ribonucleotide reductase M1 | 2.97 | 2.11 | |
| Nsmaf | neutral sphingomyelinase (N-SMase) activation associated factor | 2.43 | 2.05 | |
| Dirc2 | disrupted in renal carcinoma 2 (human) | 2.23 | 2.03 | |
| Crip1 | cysteine-rich protein 1 (intestinal) | -2.13 | -2.09 | |
| Trerf1 | transcriptional regulating factor 1 | -2.14 | -2.12 | |
| Rps19 | ribosomal protein S19 | -2.04 | -2.18 | |
| Son | Son cell proliferation protein | -2.06 | -2.23 | |
| Idb1 | inhibitor of DNA binding 1 | -2.45 | -2.36 | |
| Nnt | nicotinamide nucleotide transhydrogenase | AK087064.1 | -2.04 | -2.41 |
| Dhrs6 | dehydrogenase/reductase (SDR family) member 6 | -2.60 | -2.42 | |
| Lst1 | leukocyte specific transcript 1 | -2.26 | -2.55 | |
| Hps6 | Hermansky-Pudlak syndrome 6 | -4.86 | -4.21 | |
| Fxyd5 | FXYD domain-containing ion transport regulator 5 | BC031112.1 | -18.27 | -9.71 |
This list of 40 genes was obtained by comparing the NO (0.5 mM DETA-NO)-generated gene profile to that generated by hypoxia (1% O2) plus NO. Hyp = hypoxia treatment; NO = nitric oxide treatment.
RT-PCR analysis of genes selected form the microarray profile.
| Symbol | Ac | Hyp | NO | Hyp | NO |
| Vegf1 | 5.7 ± 0.27 | 2.0 ± 0.14 | 5.5 ± 0.84 | 3.0 ± 0.46 | |
| Ddit4 | 16.6 ± 0.58 | 3.6 ± 0.53 | 2.4 ± 0.37 | 1.4 ± 0.30 | |
| Sesn2 | 2.0 ± 0.47 | 4.2 ± 0.33 | 2.5 ± 0.64 | 3.6 ± 0.70 | |
| Bnip3 | 24.1 ± 0.42 | 2.3 ± 0.40 | 3.6 ± 0.57 | 2.2 ± 0.56 | |
| Trib3 | 3.0 ± 0.51 | 3.4 ± 0.61 | 1.5 ± 0.32 | 1.7 ± 0.35 | |
| Atf3 | 4.6 ± 0.54 | 1.3 ± 0.27 | 0.9 ± 0.35 | 0.9 ± 0.31 | |
| Frat2 | 2.0 ± 0.45 | 1.3 ± 0.43 | 2.1 ± 0.63 | 1.6 ± 0.51 | |
| Cdkn1a | 3.6 ± 0.61 | 2.3 ± 0.28 | 5.3 ± 1.33 | 4.2 ± 1.30 | |
| Scd1 | 1.3 ± 0.20 | 0.9 ± 0.60 | 1.0 ± 0.30 | 1.4 ± 0.54 | |
RAW cells were subjected to hypoxia (1% O2) or NO (0.5 mM DETA-NO) for 6 h and primary macrophages for 12 h. Whole cell mRNA was isolated and analyzed by qRT-PCR. Expression changes of 9 genes were evaluated in relation to the values obtained in parallel for 16S ribosomal protein obtained from 4 individual experiments. Hyp = hypoxic treatment; NO = nitric oxide treatment.
Figure 2Proteomics data of macrophages subjected to hypoxia for 6 hour vs. untreated cells. The scanned gel contains four samples for each treatment (untreated or hypoxia (1% O2) treated) and a column comparing the median intensities of the same spot for the four samples in each treatment. Spot colors indicate: upregulation (red), downregulation (green), no change in regulation (dark/black). Student t-test for significantly regulated spots (< 0.05) is indicated by blue vertical bars.
Figure 3Proteomics data comparing effects of nitric oxide on hypoxia regulated spots. RAW cells were subjected for 6 hours to hypoxia (1% O2) or hypoxia plus NO (0.5 mM DETA-NO). The scanned gel contains four samples for each treatment (hypoxia or hypoxia plus NO) and a column comparing the median intensities of the same spot for the four samples in each treatment. Spot colors indicate: upregulation (red), downregulation (green), no change in regulation (dark/black). Student t-test for significantly regulated spots (< 0.05) is indicated by blue vertical bars.